Mulvany – who left BenevolentAI when it listed on the Amsterdam stock exchange in 2022 and retains a sizeable stake in the company – took the reins from former LEO Pharma and Bayer executive ...

Before setting up BenevolentAI Mulvany was CEO of Proximagen, a UK-listed biotech specialising in neurodegenerative diseases that was sold to Upsher-Smith Laboratories for $553 million in 2012.